The primary objective of this study was to compare the safety of four fixed-dose regimens of edoxaban with warfarin in patients with non-valvular atrial fibrillation (AF). In this 12-week, parallel-group, multicentre, multinational study, 1,146 patients with AF and risk of stroke were randomised to edoxaban 30 mg qd, 30 mg bid, 60 mg qd, or 60 mg bid or warfarin dose-adjusted to a target international normalised ratio of 2.0–3.0.
2010 年 9 月 10 日
Author(s): Jeffrey Weitz, Stuart Connolly, Isha Patel, Diego Salazar, Shashank Rohatagi, Mendel Jansen, Helen Kastrissios, Jingjing Jin, Satoshi Kunitada
Year: 2010 年 9 月 1 日
Recommended for you